Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low – What’s Next?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $15.31 and last traded at $16.95, with a volume of 1259016 shares changing hands. The stock had previously closed at $15.79.

Wall Street Analyst Weigh In

A number of research firms recently commented on GPCR. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating on the stock. JMP Securities restated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Performance

The firm has a market capitalization of $971.96 million, a price-to-earnings ratio of -22.91 and a beta of -2.37. The business’s 50 day moving average is $23.52 and its 200-day moving average is $30.73.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. Equities research analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Deep Track Capital LP increased its position in Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after acquiring an additional 1,579,492 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Structure Therapeutics by 196.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after purchasing an additional 820,589 shares during the period. Janus Henderson Group PLC raised its position in shares of Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after buying an additional 602,609 shares during the last quarter. Vestal Point Capital LP lifted its stake in shares of Structure Therapeutics by 50.0% in the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after buying an additional 575,000 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in Structure Therapeutics during the fourth quarter worth about $13,560,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.